Skip to main content
Funded Studies

Michael A. Schwarzschild, MD, PhD

Professor of Neurology at Massachusetts General Hospital

Location: Boston, MA United States

Michael A. Schwarzschild, MD, PhD, is a neurologist at Massachusetts General Hospital and Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. Schwarzschild’s research investigates genetic and environmental factors linked to Parkinson’s disease and translates insights gained from laboratory models to clinical trials. His group discovered neuroprotective properties of adenosine A2A receptor blockers including caffeine in mouse models of Parkinson’s. His leadership of international academic-industry conferences on brain A2A receptors helped foster further development of A2A blockers, one of which received FDA approval in 2019 to treat Parkinson’s. Through cross-disciplinary collaboration, his team demonstrated that the antioxidant urate can serve as a predictor of Parkinson’s progression as well as risk, and that it confers protection in lab models. Based on these findings they pursued urate-elevating drug therapy strategy culminating in a major Phase III trial, which unfortunately found no evidence of disease modification in early Parkinson’s.

Since 2012 he has co-led the Parkinson Study Group (PSG), a network of North American Parkinson’s trialists dedicated to improving therapy for people with Parkinson’s.


Associated Grants

  • Assessing the Potential of Low-Dose Carbon Monoxide Therapy in Parkinson’s Disease

    2021


  • Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD

    2020


  • From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s Disease

    2020


  • Purine Biomarkers of LRRK2-Associated Parkinson's Disease

    2018


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.